MedTrace Logo

Glucagon Resistance in Patients With MASLD and T2DM

NCT07246421 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-02-04

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate the sensitivity to glucagon in patients with type 2 diabetes mellitus (T2DM), with and without metabolic associated fatty liver disease (MASLD).

The main questions it aims to answer are:

1. Is the sensitivity to glucagon with respect to hepatic FA oxidation and suppression of VLDL-TG secretion impaired in humans with T2DM and MASLD?
2. Is glucagon resistance and MASLD reflected in an aberrated lipidomic/metabolomic profile in blood and adipose tissue?

Researchers will compare patients with T2DM with and without MASLD to see if the response to basal and high levels of glucagon differs between the groups.

Participants will attend 2 short visits and 1 full-day visit, including:

* Body scan (DXA) to check fat and bone composition
* MRI to measure liver fat.
* Blood tests.
* Ultrasound to check liver stiffness and scarring.
* Fat biopsies
* 8-hour hormone (including glucagon) and tracer infusion
* PET-CT scans

Conditions

  • Metabolic Associated Fatty Liver Disease
  • Type 2 Diabetes (T2DM)

Interventions

OTHER

Glugagon

Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers. \[11C\]palmitate PET during low and high dose glucagon.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-29
Primary Completion
2027-07-31
Completion
2028-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07246421 on ClinicalTrials.gov